202 related articles for article (PubMed ID: 36402986)
21. Combined hepatocellular-cholangiocarcinoma: from genesis to molecular pathways and therapeutic strategies.
Gurzu S; Szodorai R; Jung I; Banias L
J Cancer Res Clin Oncol; 2024 May; 150(5):270. PubMed ID: 38780656
[TBL] [Abstract][Full Text] [Related]
22. Torin2 overcomes sorafenib resistance via suppressing mTORC2-AKT-BAD pathway in hepatocellular carcinoma cells.
Hu YT; Shu ZY; Jiang JH; Xie QF; Zheng SS
Hepatobiliary Pancreat Dis Int; 2020 Dec; 19(6):547-554. PubMed ID: 33051131
[TBL] [Abstract][Full Text] [Related]
23. Combined hepatocellular-cholangiocarcinoma with stem cell features, ductal plate malformation subtype: a case report and proposal of a new subtype.
Terada T
Int J Clin Exp Pathol; 2013; 6(4):737-48. PubMed ID: 23573322
[TBL] [Abstract][Full Text] [Related]
24. A novel murine model of combined hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Xu RC; Wang F; Sun JL; Abuduwaili W; Zhang GC; Liu ZY; Liu TT; Dong L; Shen XZ; Zhu JM
J Transl Med; 2022 Dec; 20(1):579. PubMed ID: 36494846
[TBL] [Abstract][Full Text] [Related]
25. Prognostic values of tissue-resident CD8
Chen L; Huang H; Huang Z; Chen J; Liu Y; Wu Y; Li A; Ge J; Fang Z; Xu B; Zheng X; Wu C
World J Surg Oncol; 2023 Apr; 21(1):124. PubMed ID: 37024870
[TBL] [Abstract][Full Text] [Related]
26. Intrahepatic cholangiocarcinoma: new insights in pathology.
Sempoux C; Jibara G; Ward SC; Fan C; Qin L; Roayaie S; Fiel MI; Schwartz M; Thung SN
Semin Liver Dis; 2011 Feb; 31(1):49-60. PubMed ID: 21344350
[TBL] [Abstract][Full Text] [Related]
27. Contrast-enhanced ultrasound (CEUS) for differentiating between hepatocellular and cholangiocellular carcinoma.
Bohle W; Clemens PU; Heubach T; Zoller WG
Ultraschall Med; 2012 Dec; 33(7):E191-E195. PubMed ID: 22194045
[TBL] [Abstract][Full Text] [Related]
28. Clinicopathological Features and Post-resection Prognosis of Double Primary Hepatocellular Carcinoma and Intrahepatic Cholangiocarcinoma.
Jung DH; Hwang S; Kim KH; Hong SM; Lee YJ; Ahn CS; Moon DB; Ha TY; Song GW; Park GC; Yu ES; Lee SG
World J Surg; 2017 Mar; 41(3):825-834. PubMed ID: 27812807
[TBL] [Abstract][Full Text] [Related]
29. Do the existing staging systems for primary liver cancer apply to combined hepatocellular carcinoma-intrahepatic cholangiocarcinoma?
Zhou Q; Cai H; Xu MH; Ye Y; Li XL; Shi GM; Huang C; Zhu XD; Cai JB; Zhou J; Fan J; Ji Y; Sun HC; Shen YH
Hepatobiliary Pancreat Dis Int; 2021 Feb; 20(1):13-20. PubMed ID: 33160852
[TBL] [Abstract][Full Text] [Related]
30. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma.
Sammon J; Fischer S; Menezes R; Hosseini-Nik H; Lewis S; Taouli B; Jhaveri K
Cancer Imaging; 2018 Feb; 18(1):8. PubMed ID: 29486800
[TBL] [Abstract][Full Text] [Related]
31. Oncogenic driver genes and tumor microenvironment determine the type of liver cancer.
Wang G; Wang Q; Liang N; Xue H; Yang T; Chen X; Qiu Z; Zeng C; Sun T; Yuan W; Liu C; Chen Z; He X
Cell Death Dis; 2020 May; 11(5):313. PubMed ID: 32366840
[TBL] [Abstract][Full Text] [Related]
32. PKI-587 and sorafenib alone and in combination on inhibition of liver cancer stem cell proliferation.
Gedaly R; Galuppo R; Musgrave Y; Angulo P; Hundley J; Shah M; Daily MF; Chen C; Cohen DA; Spear BT; Evers BM
J Surg Res; 2013 Nov; 185(1):225-30. PubMed ID: 23769634
[TBL] [Abstract][Full Text] [Related]
33. Microvessel density and angiogenesis in primary hepatic malignancies: Differential expression of CD31 and VEGFR-2 in hepatocellular carcinoma and intrahepatic cholangiocarcinoma.
Bösmüller H; Pfefferle V; Bittar Z; Scheble V; Horger M; Sipos B; Fend F
Pathol Res Pract; 2018 Aug; 214(8):1136-1141. PubMed ID: 29935812
[TBL] [Abstract][Full Text] [Related]
34. Longterm prognosis of combined hepatocellular carcinoma-cholangiocarcinoma following liver transplantation and resection.
Jung DH; Hwang S; Song GW; Ahn CS; Moon DB; Kim KH; Ha TY; Park GC; Hong SM; Kim WJ; Kang WH; Kim SH; Yu ES; Lee SG
Liver Transpl; 2017 Mar; 23(3):330-341. PubMed ID: 28027599
[TBL] [Abstract][Full Text] [Related]
35. PKI-587 and sorafenib targeting PI3K/AKT/mTOR and Ras/Raf/MAPK pathways synergistically inhibit HCC cell proliferation.
Gedaly R; Angulo P; Hundley J; Daily MF; Chen C; Evers BM
J Surg Res; 2012 Aug; 176(2):542-8. PubMed ID: 22261591
[TBL] [Abstract][Full Text] [Related]
36. Activation of phosphatidylinositol 3-kinase/Akt signaling pathway mediates acquired resistance to sorafenib in hepatocellular carcinoma cells.
Chen KF; Chen HL; Tai WT; Feng WC; Hsu CH; Chen PJ; Cheng AL
J Pharmacol Exp Ther; 2011 Apr; 337(1):155-61. PubMed ID: 21205925
[TBL] [Abstract][Full Text] [Related]
37. Differentiating combined hepatocellular and cholangiocarcinoma from mass-forming intrahepatic cholangiocarcinoma using gadoxetic acid-enhanced MRI.
Hwang J; Kim YK; Park MJ; Lee MH; Kim SH; Lee WJ; Rhim HC
J Magn Reson Imaging; 2012 Oct; 36(4):881-9. PubMed ID: 22730271
[TBL] [Abstract][Full Text] [Related]
38. Geographic variation of intrahepatic cholangiocarcinoma, extrahepatic cholangiocarcinoma, and hepatocellular carcinoma in the United States.
Altekruse SF; Petrick JL; Rolin AI; Cuccinelli JE; Zou Z; Tatalovich Z; McGlynn KA
PLoS One; 2015; 10(3):e0120574. PubMed ID: 25837669
[TBL] [Abstract][Full Text] [Related]
39. Impact of incidental/misdiagnosed intrahepatic cholangiocarcinoma and combined hepatocellular cholangiocarcinoma on the outcomes of liver transplantation: an institutional case series and literature review.
Gupta R; Togashi J; Akamatsu N; Sakamoto Y; Kokudo N
Surg Today; 2017 Aug; 47(8):908-917. PubMed ID: 28124125
[TBL] [Abstract][Full Text] [Related]
40. Targeting PI3K/Akt/mTOR Pathway Identifies Differential Expression and Functional Role of IL8 in Liver Cancer Stem Cell Enrichment.
Kahraman DC; Kahraman T; Cetin-Atalay R
Mol Cancer Ther; 2019 Nov; 18(11):2146-2157. PubMed ID: 31439713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
